Table 2 Characteristics of the trials eligible for meta-analysis
Article (Jadad score) | Design | Number of patients | Delivery method | Type of surfactant | Surfactant dosing (total) | Treatment duration | Number of deaths | Ventilation-free daysa | Duration of ventilationb | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | Surfactant | Control | Surfactant | Control | Surfactant | |||||||
Weg and colleagues, 1994 [16] (score 5) | Multicenter: USA, Canada | 51 (control = 17, group 1 = 17, group 2 = 17) | Aerosolized | Exosurf (synthetic, no surfactant protein) | 13.5 mg DPPC/ml (group 1, 21.9 mg DPPC/kg/day; Group 2, 43.5 mg DPPC/kg/day) | Maximum 120 hours for all groups | 8 | Group 1 = 7, group 2 = 6 | NA | NA | NA | NA |
Anzueto and colleagues, 1996 [17] (score 5) | Multicenter: USA, Spain, France | 725 (control = 361, surfactant = 364) | Aerosolized | Exosurf (synthetic, no surfactant protein) | 13.5 mg DPPC/ml (112 mg DPPC/kg/day) | Maximum 5 days | 143 | 145 | NA | NA | 16.4 (0.9) | 16.0 (1.0) |
Gregory and colleagues, 1997 [18] (score 2) | Multicenter: USA | 59 (control = 16, group 1 = 8, group 2 = 16, group 3 = 19) | Intratracheal | Survanta bovine lung extract (containing SP-B and SP-C) | Group 1, 50 mg/kg LBW (maximum 8 doses); group 2, 100 mg/kg LBW (maximum 4 doses); group 3, 100 mg/kg LBW (maximum 8 doses) | Maximum 96 hours for all groups | 7 | Group 1 = 4, group 2 = 3, group 3 = 3 | NA | NA | 10 | Group 1 = 15c, group 2 = 7c, group 3 = 10c |
Spragg and colleagues, 2003 [19] (score 2) | Multicenter: USA, Canada | 40 (control= 13, group 1 = 15, group 2 = 12) | Intratracheal | Venticute (rSP-C-based surfactant) | Group 1, 1 mg/kg LBW (maximum 4 doses); group 2, 0.5 ml/kg LBW (maximum 4 doses) | 24 hours for all groups | 5 | Group 1 = 3, group 2 = 4 | 6 (0–15) | Group 1= 5 (0–18), group 2 = 4 (0–12) | NA | NA |
Spragg and colleagues, 2004 [20] (score 4) | Multicenter: Europe, South Africa | 227 (control = 109, surfactant = 118) | Intratracheal | rSP-C-based surfactant | 1 mg/kg LBW (maximum 4 doses) | 24 hours | 43 | 46 | 0 (0–20) | 0 (0–19) | NA | NA |
Spragg and colleagues, 2004 [20] (score 4) | Multicenter: USA, Canada | 221 (control = 115, surfactant = 106) | Intratracheal | rSP-C-based surfactant | 1 mg/kg LBW (maximum 4 doses) | 24 hours | 29 | 34 | 6 (0–21) | 3.5 (0–21) | NA | NA |